SPOTLIGHT -
New Standard of Care in Relapsed, Refractory Myeloma?
In this video, Antonio Palumbo, MD, discusses results of the CASTOR trial, which studied daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
